Loratadine

CHEMBL998 Phase 4 Disetujui Small molecule
Half-Life
8 hours
Bioavailability
Protein Binding
Molecular Weight
382.9 g/mol
LogP
5.2
Phase
4

A second-generation, non-sedating antihistamine, loratadine blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness. It treats allergic rhinitis and chronic hives. Sold over the counter as Claritin and Alavert, the compound has the formula C22H23ClN2O2 and its minimal central nervous system penetration distinguishes it from older allergy medications.

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Berat Molekul

382,8800 g/mol

LogP

5,20

TPSA

42,40 Ų

Lipinski RO5

Lulus

Kelas Obat

Mekanisme Kerja

Second-generation H1 antihistamine with minimal CNS effects.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mekanisme

Second-generation H1 antihistamine with minimal CNS effects.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

InChI

InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

Molecular Formula

C22H23ClN2O2

HBD / HBA

- / 3

Ikatan yang Dapat Dirotasi

2

Atom Berat

27

Primary Target

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Second-generation H1 antihistamine with minimal CNS effects.

Key pharmacokinetic parameters for Loratadine: Half-life: 8 hours.

Yes, Loratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL998. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3957. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.